Polaryx Therapeutics, Inc. PLYX Working Capital

The Company has no products approved for sale and has sustained recurring net losses and negative cash flows from operations since inception. For the three months ended March 31, 2026 and 2025, the Company had a net loss of $2.5 million and $5.1 million, respectively, and used cash in operating activities of $2.1 million and $709 thousand, respectively. As of March 31, 2026, the Company had working capital of $2.5 million. Achieving profitability is dependent upon the successful development, approval, and commercialization of the Company’s product candidates and achieving a level of revenue adequate to support the Company’s cost structure. Management intends to fund future operations through additional financings, which could include private and/or public debt offerings and equity offerings. In addition, the Company may seek additional capital through arrangements with strategic partners or from other sources. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, or at all.